Billing Code 4410-09-M

DEPARTMENT OF JUSTICE

DRUG ENFORCEMENT ADMINISTRATION

MANUFACTURER OF CONTROLLED SUBSTANCES

NOTICE OF REGISTRATION

HALO PHARMACEUTICAL, INC.

By Notice dated July 30, 2012, and published in the Federal Register on August 7, 2012, 77 FR 47114, Halo Pharmaceutical, Inc., 30 North Jefferson Road, Whippany, New Jersey 07981, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Dihydromorphine (9145)	I
Hydromorphone (9150)	II

Dihydromorphine is an intermediate in the manufacture of Hydromorphone and is not for commercial distribution. The company plans to manufacture Hydromorphone HCL for sale to other manufacturers, and for the manufacture of other

controlled substance dosage units for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in 21 USC § 823(a), and determined that the registration of Halo Pharmaceutical, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Halo Pharmaceutical, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 USC § 823(a), and in accordance with 21 CFR § 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Joseph T. Rannazzisi
Deputy Assistant Administrator
Office of Diversion Control
Drug Enforcement Administration

DATED: December 14, 2012

[FR Doc. 2012-30774 Filed 12/20/2012 at 8:45 am;
Publication Date: 12/21/2012]